CKD-383 / Chong Kun Dang - LARVOL DELTA

Clinical Study to Evaluate the Food Effect of CKD-383 0.5/25/1000mg in Healthy Volunteers (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

CKD-383 FDI P1: Clinical Study to Evaluate the Food Effect of CKD-383 0.5/10/1000mg in Healthy Volunteers (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

CKD-383 FDI P1: Clinical Study to Evaluate the Food Effect of CKD-383 0.5/10/1000mg in Healthy Volunteers (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Clinical Study to Evaluate the Food Effect of CKD-383 0.5/25/1000mg in Healthy Volunteers (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State. (clinicaltrials.gov) - P1 | N=45 | Completed | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers (clinicaltrials.gov) - P1 | N=28 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029 (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150 (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Enrolling by invitation ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150 (clinicaltrials.gov) - P1 | N=30 | Enrolling by invitation | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029 (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus